Longitudinal associations between late-life depression, cerebrovascular disease and cognition.

Background: Depression and vascular disease can both be risk factors for cognitive decline. This study assessed whether indicators of vascular disease are associated with depression over time, and whether depression is associated with cognition independent of vascular disease.
Methods: Participants were 1032 community-dwelling, older adults from the Sydney Memory and Ageing Study. Depressive symptoms were measured on the 15-item Geriatric Depression Scale, and depression trajectories were classified using latent class growth modelling. Global cognition and individual cognitive domains were assessed. Indicators of vascular disease were history of stroke or transient ischaemic attack (TIA) and total white matter hyperintensities (TWMH). Generalised linear mixed modelling assessed whether vascular markers were associated with change in depressive symptoms over time. Linear mixed modelling examined relationships between depression, vascular disease indicators, and cognition.
Results: History of stroke/TIA or TWMH did not predict depression over time (p = 0.11 and p = 0.70). Baseline stroke/TIA history was associated with a decline in attention over time (b = -0.05, p = 0.04). Significant differences between latent depression trajectories classes in cognitive decline were observed, with participants who became depressed over time experiencing decline in global cognition (b = -0.04, p < 0.001), attention (b = -0.05, p < 0.001) and executive function (b = -0.05, p < 0.001), compared to the non-depressed group.
Conclusion: Our findings suggest that depression in later life may not precede cognitive decline. Instead, depressive symptoms and cognitive decline, particularly in attention and executive function, may evolve in tandem over time. This reinforces the importance of early identification and treatment of depression in older adults to potentially mitigate cognitive deterioration.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Henry Brodaty reports was provided by University of New South Wales. Henry Brodaty reports a relationship with Biogen Inc. that includes: consulting or advisory. Henry Brodaty reports a relationship with Eli Lilly and Company that includes: consulting or advisory. Henry Brodaty reports a relationship with Eisai Australia Pty Limited that includes: speaking and lecture fees. Henry Brodaty reports a relationship with Roche that includes: speaking and lecture fees. Henry Brodaty reports a relationship with Medicines Australia that includes: consulting or advisory. Henry Brodaty reports a relationship with Skin2Neuron that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Perminder S Sachdev reports financial support was provided by National Health and Medical Research Council. Perminder S Sachdev reports a relationship with Biogen Australia Pty Ltd that includes: consulting or advisory. Perminder S Sachdev reports a relationship with Roche that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Crown Copyright © 2025. Published by Elsevier B.V. All rights reserved.)